

Certificate of Registration

nqa.

This is to certify that the Quality Management System of

**SHANGHAI VENTURE BIO-TECH CO., LTD.**

Unified Social Credit Code : 913101046311103535

Operation Address : Room 313, 203, 216, 217, Building 2, No.2715 Longwu Road, Xuhui District, Shanghai, China

Registered Address : Room 313, Building 2, No.2715 Longwu Road, Xuhui District, Shanghai, China

applicable to

The R&D, Production and Sales of Drugs In-vitro Diagnostic Reagent(Details for Annex), Human Chorionicgonadotrophin(HCG)Test Paper(Colloidal Gold)(Within the Scope of License Qualification)

has been assessed and registered by NQA against the provisions of


**ISO 13485: 2016**

This registration is subject to the company maintaining a quality management system, to the above standard, which will be monitored by NQA.

Certified Clients shall accept regular surveillance assessments, the validity of certificates shall be maintained for the positive result of audit.

The information of this certificate can be checked on CNCA's website ([www.cnca.gov.cn](http://www.cnca.gov.cn))

SNQA's website : [www.snqa.com.cn](http://www.snqa.com.cn)

  
Managing Director



015



Certificate Number

**39552**

Date:

30 December 2013

Reissue Date:

24 December 2019

Valid Until:

03 September 2021

EAC Code:

13







SHANGHAI VENTURE BIO-TECH CO., LTD.

Annex

Drugs In-vitro Diagnostic Reagent

1. Morphine Test Kit (Colloidal Gold)
2. Methamphetamine Test Kit (Colloidal Gold)
3. Ketamine Test kit(Colloidal Gold)
4. Morphine / Methamphetamine Test Kit(Colloidal Gold)
5. Methylenedioxymethamphetamine Test Kit (Colloidal Gold)
6. Cocaine Test kit(Colloidal Gold)
7. Tetrahydrocannabinol Acid Test Kit (Colloidal Gold)
8. Morphine / Methamphetamine in Saliva Test (Colloidal Gold)
9. Multiple Drugs Test Kit(Colloidal Gold)

Managing Director



Certificate Number

39552

Date:

30 December 2013

Reissue Date:

24 December 2019

Valid Until:

03 September 2021

EAC Code:

13



Product name: Saliva SARS-Cov-2(2019-nCoV)Antigen Combined Test Kit (Nanocarbon Assay)      MSDS Number: SDS202009303023  
Revision Date: 30/09/2020      Page: 1 of 9  
Version: 1.0

## 1. IDENTIFICATION OF THE PRODUCT AND OF THE COMPANY/UNDERTAKING

### Product identifier

Product name : Saliva SARS-Cov-2(2019-nCoV)Antigen Combined Test Kit  
(Nanocarbon Assay)

### Recommended use of the chemical and restrictions on use

Identified use : For *in vitro* diagnostic use only  
(This product is used to qualitatively detect novel Coronavirus antigen in human saliva samples)

## 2. HAZARDS IDENTIFICATION

### Emergency Overview

This product is not considered as hazardous according to China GB standards(GB30000-2013).  
Consult a physician. Show this safety data sheet to the doctor in attendance.

### GHS-Classification- China standards(GB30000-2013)

This product is not considered as hazardous according to China GB standards(GB30000-2013).

### GHS-Labeling- China standards(GB30000-2013)

Hazard pictograms : Not available

Signal word : Not available

Hazard statements : Not applicable

Precautionary statements : **Prevention:**

P101 If medical advice is needed, have product container or label at hand.

P102 Keep out of reach of children.

P103 Read label before use.

**Response:**





Product name: Saliva SARS-Cov-2(2019-nCoV)Antigen  
Combined Test Kit (Nanocarbon Assay)  
Revision Date: 30/09/2020  
Version: 1.0

MSDS Number: SDS20200930302  
Page: 2 of 3

Not applicable

**Storage:**

Not applicable

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Physical and chemical hazards**

Not classified based on available information.

**Health hazards**

Not classified based on available information.

**Environmental hazards**

Not classified based on available information.

**Other hazards which do not result in classification**

No data available.

**3. COMPOSITION/INFORMATION ON INGREDIENTS**

Product type : Mixture

**Hazardous components**

Product component	Chemical name	CAS-No.	Classification (GB 30000.2-29 – 2013)	Concentration
Diagnostic test card	Nitrocellulose membrane	9004-70-0	Expl. 1.1, H201;	-
	PVC board	9002-86-2	Not classified	
	Fiberglass	65997-17-3	Not classified	
	Carbon nanotubes	7440-44-0	Not classified	
	N protein antibody	-	Not classified	
	S protein antibody	-	Not classified	

Product name: Saliva SARS-Cov-2(2019-nCoV)Antigen  
 Combined Test Kit (Nanocarbon Assay)  
 Revision Date: 30/09/2020  
 Version: 1.0

MSDS Number: SDS202009303023  
 Page: 3 of 9

	Sheep anti mouse IgG antibody	-	Not classified	
Desiccant	Silicon oxide	14808-60-7	Not classified	>90%
	Water	7732-18-5	Not classified	≤10%

#### 4. FIRST AID MEASURES

- General advice : Show this safety data sheet to the doctor in attendance.
- If inhaled : Not required under normal conditions of use.  
 Move to fresh air.  
 If unconscious place in recovery position and seek medical advice.  
 If symptoms persist, call a physician.
- In case of skin contact : Not required under normal conditions of use.  
 Wash off with soap and plenty of water.  
 Consult a physician.
- In case of eye contact : Not required under normal conditions of use.  
 Flush eyes with water as a precaution.  
 Remove contact lenses.  
 Protect unharmed eye.  
 If symptoms persist, call a physician.
- If swallowed : Not required under normal conditions of use.  
 Rinse mouth with water.  
 If symptoms persist, call a physician.

#### Notes to physician

- Symptoms : None known or anticipated symptoms.
- Treatment : Treat symptomatically.

#### 5. FIREFIGHTING MEASURES

- Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
 Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

Product name: Saliva SARS-Cov-2(2019-nCoV)Antigen  
Combined Test Kit (Nanocarbon Assay)  
Revision Date: 30/09/2020  
Version: 1.0

MSDS Number: SDS202009303023  
Page: 4 of 9

- Unsuitable extinguishing media : For this product no limitations of extinguishing agents are given.
- Specific hazards during firefighting : There is no explosion or fire hazard.  
Development of hazardous combustion gases or vapors possible in the event of fire.
- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.
- Further information : Prevent fire extinguishing water from contaminating surface water or the ground water system.  
Fire residues and contaminated fire extinguishing water must be disposed of in accordance with local regulations.

## 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions : Keep sufficient ventilation at working place.  
Avoid dust formation.  
Avoid breathing dust, vapor, mist and gas.  
For personal protection see section 8.
- Environmental precautions : Prevent product from entering soil, drains and waterways.
- Methods for cleaning up : Sweep up and shovel.  
Keep in suitable, closed containers for disposal.
- Additional advice : Comply with all applicable national and local regulations.

## 7. HANDLING AND STORAGE

### Handling

- Advice on safe handling : Work under hood or special environment.  
Provide sufficient ventilation at working place.  
For personal protection see section 8.  
Dispose of rinse water in accordance with local and national regulations.
- Advice on protection against fire and explosion : Normal fire protective measure.

### Storage

- Requirements for storage areas and containers : Keep containers tightly closed in a dry, cool and well-ventilated place.

Product name: Saliva SARS-Cov-2(2019-nCoV)Antigen  
Combined Test Kit (Nanocarbon Assay)  
Revision Date: 30/09/2020  
Version: 1.0

MSDS Number: SDS202009303023  
Page: 5 of 9

Keep locked up or in an area accessible only to qualified or authorized persons.  
Store in according to instruction.

Materials to avoid : Fluorides, hydrogen fluoride, strong acids and strong alkalis(desiccant only).

Other data : Hazardous decomposition products formed under fire conditions.  
- Carbon oxides.

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Components with workplace control parameters

Contains no ingredient with known occupational exposure limit.

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
				GBZ 2.1-2007

### Engineering measures

Technical measures and appropriate working operations should be given priority over the use of personal protective equipment.

### Personal protective equipment

Respiratory protection : No personal respiratory protective equipment normally required.

Hand protection : Protective gloves.

Eye protection : Safety glasses.

Skin and body protection : Protective clothing.

Hygiene measures : In accordance with good hygiene practice.  
Wash hands before breaks and at the end of workday.  
When using do not eat or drink.



Product name: Saliva SARS-Cov-2(2019-nCoV)Antigen  
Combined Test Kit (Nanocarbon Assay)  
Revision Date: 30/09/2020  
Version: 1.0

MSDS Number: SDS202009303023  
Page: 6 of 9

## 9. PHYSICAL AND CHEMICAL PROPERTIES

### Appearance

Physical state/appearance : Diagnostic kit containing a diagnostic test card and a desiccant.  
Color : White  
Odor : No odor  
Odor Threshold : No data available

### Safety data

Flash point : Does not flash  
Ignition temperature : No data available  
Lower explosion limit : No data available  
Upper explosion limit : No data available  
Flammability (solid, gas) : Non flammable  
Oxidizing properties : No data available  
Auto-ignition temperature : No data available  
Decomposition temperature : No data available  
Molecular weight : No data available  
pH : No data available  
Melting point/freezing point : No data available  
Boiling point : No data available  
Sublimation point : No data available  
Vapour pressure : No data available  
Density : No data available  
Bulk density : No data available  
Water solubility : Insoluble in water  
Partition coefficient: n-octanol/water : No data available  
Solubility in other solvents : No data available  
Viscosity, dynamic : No data available  
Viscosity, kinematic : No data available  
Flow time : No data available  
Impact sensitivity : No data available  
Relative vapour density : No data available  
Surface tension : No data available  
Evaporation rate : No data available

## 10. STABILITY AND REACTIVITY



Product name: Saliva SARS-Cov-2(2019-nCoV)Antigen  
Combined Test Kit (Nanocarbon Assay)  
Revision Date: 30/09/2020  
Version: 1.0

MSDS Number: SDS202009303023  
Page: 7 of 9

Hazardous reactions	: This product is non-reactive under normal conditions of use, storage and transport.
Chemical stability	: The product is chemically stable under standard ambient conditions (room temperature).
Conditions to avoid	: Keep away from heat, flame, sparks and other ignition sources.
Materials to avoid	: Fluorides, hydrogen fluoride, strong acids and strong alkalis(desiccant only).
Hazardous decomposition products	: Hazardous decomposition products formed under fire conditions. - Carbon oxides.

## 11. TOXICOLOGICAL INFORMATION

### Acute toxicity

Not classified based on available information.

### Skin corrosion/irritation

Not classified based on available information.

### Serious eye damage/eye irritation

Not classified based on available information.

### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

Not classified based on available information.

### Germ cell mutagenicity

Not classified based on available information.

### Carcinogenicity

Not classified based on available information.

### Reproductive toxicity

Not classified based on available information.

#### STOT - single exposure

Not classified based on available information.

#### STOT - repeated exposure

Not classified based on available information.

Product name: Saliva SARS-Cov-2(2019-nCoV)Antigen  
Combined Test Kit (Nanocarbon Assay)  
Revision Date: 30/09/2020  
Version: 1.0

MSDS Number: SDS202009303023  
Page: 8 of 9

**Aspiration toxicity**

Not classified based on available information.

**12. ECOLOGICAL INFORMATION****Ecotoxicity****Ecotoxicology Assessment**

Acute aquatic toxicity : Not classified based on available information.

Chronic aquatic toxicity : Not classified based on available information.

**Persistence and degradability**

No data available

**Bioaccumulative potential**

Partition coefficient: n-octanol/water : No data available

**Mobility in soil**

No data available

**13. DISPOSAL CONSIDERATIONS****Disposal methods**

General advice : Dispose of in accordance with all applicable local, state and federal regulations.

**14. TRANSPORT INFORMATION****International transport regulations****CHINA ROAD(Land transport, JT/T 617-2018)**

UN Number: not regulated/non-dangerous goods

Proper Shipping Name: N/A

Hazard classes: N/A

Packaging group: N/A

**INTERNATIONAL MARITIME DANGEROUS GOODS(IMDG, 39-18)**

UN Number: not regulated/non-dangerous goods

Proper Shipping Name: N/A

Hazard classes: N/A

Packaging group: N/A



Shanghai Ruitu Co., Ltd. did not test, certify, or approve the product described in this Material Safety Data Sheet (MSDS), and all information in this MSDS was provided by the supplier or was reproduced from publicly available regulatory data sources. Shanghai Ruitu Co., Ltd. makes no representations or warranties regarding the completeness or accuracy of the information in this MSDS and disclaims all liability in connection with the use of this information or the product described in this MSDS. - www.msds-china.com

Product name: Saliva SARS-Cov-2(2019-nCoV)Antigen  
Combined Test Kit (Nanocarbon Assay)  
Revision Date: 30/09/2020  
Version: 1.0

MSDS Number: SDS202009303023  
Page: 9 of 9

**INTERNATIONAL AIR TRANSPORT ASSOCIATION(IATA, 61th edition)**

UN Number: not regulated/non-dangerous goods  
Proper Shipping Name: N/A  
Hazard classes: N/A  
Packaging group: N/A

**15. REGULATORY INFORMATION**

Regulations on the Control over Safety of Dangerous Chemicals (Decree No. 591 of the State Council of the People's Republic of China)  
General rules for preparation of chemical safety data sheet (GB16483-2008)  
Rules for classification and labelling of chemicals(GB30000-2013)  
Classification and labels of dangerous chemical substances commonly used (GB13690-2009)  
List of dangerous goods (GB12268-2012)  
Classification and code of dangerous goods (GB6944-2012)

**16. OTHER INFORMATION****Further information**

Revision Date: 30/09/2020

**Disclaimer:**

This MSDS is intended to provide a brief summary of our knowledge and guidance regarding the use of this material. The information contained here has been compiled from sources considered by us to be dependable and is accurate to the best of our knowledge.

This information is offered in good faith. Each user of this material needs to evaluate the conditions of use and design the appropriate protective mechanisms to prevent employee exposures, property damage or release to the environment. We assumed no responsibility for injury to the recipient or third persons, or for any damage to any property resulting from misuse of the product.

**\*\*End of Material Safety Data Sheet\*\***



EN 62366-1:2015 availability assessment report			
Clause	Requirement + Test	Result - Remark	Verdict
<b>4</b>	<b>GENERAL REQUIREMENTS</b>		
4.1	General Requirements		
4.1.1	Usability Engineering Process		
	Has the manufacturer established, documented and maintained a usability engineering process to provide Safety for the patient, user and others related to usability for the product?	CE-01-07.1 Labels CE-01-07.2 Instruction For Use	OK
	Does the Process addressed user interactions with the medical device according to the accompanying document including, but not limited to transport, storage, installation, operation, maintenance, repair and disposal?	CE-01-07.1 Labels CE-01-07.2 Instruction For Use	OK
4.1.2	Residual risk		
	Are Residual Risks associated with Usability of the medical Device presumed to be acceptable, unless there is objective evidence to the contrary and documented?	CE-01-09 Risk Management Report	OK
4.1.3	Information for Safety		
	manufacturer subject the information for safety used as a risk control to the usability engineering process (e.g., warnings or limitation of use in the accompanying documents, marking, etc.) in the UE file and Accompanying documents.	CE-01-07.1 Labels CE-01-07.2 Instruction For Use	OK
	Disregarding such information for safety is considered beyond any further reasonable means of risk control	CE-01-07.1 Labels CE-01-07.2 Instruction For Use	OK
4.2	Usability Engineering File		
	The results of the usability engineering process are recorded in the usability engineering file	CE Technical Files	OK
	The records and other documents that make up the usability engineering file form part of other documents and files (e.g., a manufacturer's product design file or risk management file), (see List of documents make up the UE file)	CE Technical Files	OK
4.3	Scaling of the Usability Engineering effort		

	The usability engineering process is scaled based on the significance of any modifications depending on the results of the risk analysis and documented	CE-01-09 Risk Management Report	
5	USABILITY ENGINEERING PROCESS		
5.1	Application specification		
	Application of Medical Device in the usability engineering file is specified by the manufacturer and includes	CE-01-07.1 Labels CE-01-07.2 Instruction For Use	OK
	– intended medical indication (e.g., conditions(s) or disease(s) to be screened, monitored, treated, diagnosed, or prevented);		
	– intended patient population (e.g., age, weight, health, condition);		
	– intended part of the body or type of tissue applied to or interacted with;		
	– intended conditions of use (e.g., environment including hygienic requirements, frequency of use, location, mobility); and		
	– operating principle(s)		
5.2	Frequently used functions		
	Are frequently used functions that involve User interaction with the Medical Device are determined and recorded in the usability engineering file?	CE-01-07.1 Labels CE-01-07.2 Instruction For Use	OK
5.3	Identification of hazards and hazardous situations related to usability		
5.3.1	Identification of characteristics to safety		
	Identification of characteristics related to safety (part of a risk analysis) that focuses on usability performed according to ISO 14971:2019.	CE-01-09 Risk Management Report	OK
	During the identification characteristics related to safety, the following are considered: – application specification, including user profile(s); and – frequently used functions.		
	Results of this identification characteristics related to safety recorded in the usability engineering file		
5.3.2	Identification of known or foreseeable hazards and hazardous situations		

	manufacturer has identified known or foreseeable hazards (part of a risk analysis) related to usability according to ISO 14971:2019.	CE-01-09 Risk Management Report	OK
	Identification of hazards considered hazards to patients, users and other persons	CE-01-09 Risk Management Report	OK
	Reasonably foreseeable sequences or combinations of events involving the user INTERFACE that can result in a HAZARDOUS SITUATION associated with the MEDICAL DEVICE were identified. The SEVERITY of the resulting possible HARM is determined.	CE-01-09 Risk Management Report	OK
	<p>During the identification of HAZARDS and HAZARDOUS SITUATIONS, the following was considered:</p> <ul style="list-style-type: none"> <li>– application specification, including user profile(s);</li> <li>– task related requirements;</li> <li>– context of use;</li> <li>– information on HAZARDS and HAZARDOUS SITUATIONS known for existing USER INTERFACES of MEDICAL DEVICES of a similar type, if available;</li> <li>– preliminary USE SCENARIOS;</li> <li>– possible USE ERRORS;</li> <li>– if an incorrect mental model of the operation of the MEDICAL DEVICE can cause a USE ERROR resulting in a HAZARDOUS SITUATION; and</li> <li>– results of the review of the USER INTERFACE</li> </ul>	CE-01-09 Risk Management Report	OK
	The results of this identification of HAZARDS, HAZARDOUS SITUATIONS and SEVERITY are recorded in the USABILITY ENGINEERING FILE.	CE-01-09 Risk Management Report	OK
5.4	Primary operating functions		
	The manufacturer has determined the primary operating functions and recorded in the usability engineering file	CE-01-07.1 Labels CE-01-07.2 Instruction For Use	OK
	The inputs to the primary operating functions include frequently used functions and functions related to Safety of the Medical Device	CE-01-07.1 Labels CE-01-07.2 Instruction For Use	OK
5.5	Usability Specification		
	manufacturer developed a usability specification recorded in the usability engineering file as part of the usability engineering process	CE-01-07.1 Labels CE-01-07.2 Instruction For Use	OK



	The usability specification recorded in usability engineering file. The usability specification may be integrated into other specifications	CE-01-07.1 Labels CE-01-07.2 Instruction For Use	OK
	The usability specification includes: – application specification; – primary operating functions – hazards and Hazardous Situations related to the Usability; and – known or foreseeable use errors associated with the Medical Device	CE-01-07.1 Labels CE-01-07.2 Instruction For Use CE-01-09 Risk Management Report	OK
	The usability specification describes at least:	CE-01-07.1 Labels CE-01-07.2 Instruction For Use	OK
	– use scenarios related to the primary operating functions equipment, including – frequent Use Scenarios, and – reasonably foreseeable worst case Use Scenarios;	CE-01-09 Risk Management Report	OK
	– User Interface requirements for the primary operating functions equipment including those to mitigate Risk;	CE-01-07.1 Labels CE-01-07.2 Instruction For Use CE-01-09 Risk Management Report	OK
	– Requirements for determining whether primary operating functions are easily recognizable by the User.	CE-01-07.1 Labels CE-01-07.2 Instruction For Use	OK
5.6	Usability validation plan		
	The manufacturer has developed and maintains a usability validation plan specifying:	CE-01-15 Test Reports	OK
	– any method used for validation of the usability of the primary operating functions;	CE-01-15 Test Reports	OK
	– the criteria for determining successful validation of the usability of the primary operating functions based on the usability specification; and	CE-01-15 Test Reports	OK
	– the involvement of representative intended users	CE-01-15 Test Reports	OK
	usability validation performed in a laboratory setting ..... :	CE-01-15 Test Reports	OK

	usability validation performed in the actual use environment.....	CE-01-15 Test Reports	OK
	The usability validation plan addresses: – frequent Use Scenarios, and – reasonably foreseeable worst case use scenarios that are identified in the usability specification	CE-01-15 Test Reports	OK
	The usability validation plan recorded in the usability engineering file	CE-01-15 Test Reports	OK
5.7	User interface design and implementation		
	Manufacturer designed and implemented the user interface as described in the usability Specification utilizing, as appropriate, usability engineering methods and techniques	CE Technical Files	OK
5.8	Usability verification		
	Manufacturer verified the implementation of the Medical Device User interface design according to the usability specification	CE-01-15 Test Reports	OK
	The results of the verification are recorded in usability engineering file	CE-01-15 Test Reports	OK
5.9	Usability Validation		
	The manufacturer has validated the Usability of the Medical Device according to the usability validation plan	CE-01-11 Clinic Evaluation Report	OK
	The results are recorded in the usability engineering file	CE-01-11 Clinic Evaluation Report	OK
	For the acceptance criteria documented in the usability validation plan that are not met: - further User Interface design and implementation activities are performed; or - if further improvement is not practicable, the MANUFACTURER may gather and review data and literature to determine if the medical benefits of the INTENDED USE outweigh the RISK arising from USABILITY problems To perform this step, the MANUFACTURER needs to estimate the RISK arising from USABILITY problems.	CE-01-11 Clinic Evaluation Report	OK

6	Accompanying documents		
	The Accompanying document includes a summary of the Medical Device application specification	CE-01-05 Product Description	OK
	A concise description of the Medical Device, its operating principles, significant physical and performance characteristics and intended User Profile are included in the Accompanying document	CE-01-05 Product Description	OK
	The Accompanying document is written at a level consistent with the intended operator profile	CE-01-05 Product Description	OK
	The Accompanying document for equipment are, optionally, provided electronically	CE-01-05 Product Description	OK
	Usability engineering process includes the information that will need to be provided as a hard copy or as markings on Medical Device when accompanying documents are provided electronically	CE-01-05 Product Description	OK
7	training and materials for training		
	The required training on the MEDICAL DEVICE for safe and effective use of PRIMARY OPERATING FUNCTIONS by the intended USER is given by:	CE-01-07.1 Labels CE-01-05 Product Description	OK
	– necessary training materials provided by the manufacturer;		
	– necessary training materials are available; or		
	– the manufacturer provides TRAINING		
	The ACCOMPANYING DOCUMENT describes the available training options (Recommendation: ACCOMPANYING DOCUMENT include the suggested duration and frequency of such training)		
	INTENDED USE AND USER PROFILE(S) are the basis for TRAINING and TRAINING material		



EC Technical Documentation (Part B)	CE-01
17 availability assessment report	A/0

EN 62366-1:2015 availability assessment report			
Clause	Requirement + Test	Result - Remark	Verdict

[illegible]